Board changes at Cytos Biotechnology
This article was originally published in Scrip
Cytos Biotechnology (Switzerland) has elected its vice-chairman, Dr Thomas Hecht, to succeed Dr François L'Eplattenier as chairman, effective from the company's next shareholders' meeting on April 22nd. Dr Thorlef Spickschen, who has been a member of Cytos's board of directors since April 2003, will become vice-chairman.
You may also be interested in...
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot
Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.